Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967774 | 0.86 | AHR (0.48) | AHRPTGS1PTGS2DHODH | |
| SCHEMBL9967780 | 0.86 | PTGS1 (0.47) | PTGS1PTGS2DHODH | |
| SCHEMBL9967784 | 0.77 | AHR (0.38) | AHRDHODH | |
| SCHEMBL16638194 | 0.77 | AHR (0.50) | AHRPTGS1RAPGEF4 | |
| SCHEMBL23465240 | 0.76 | AHR (0.33) | AHRPTGS1PTGS2CMA1 | |
| SCHEMBL257116 | 0.73 | AHR (0.36) | AHRPTGS1PTGS2RAPGEF4 | |
| SCHEMBL19120301 | 0.73 | EPAS1 (0.34) | PTGS1PTGS2 | |
| SCHEMBL16618475 | 0.73 | RAPGEF4 (0.36) | AHRPTGS1PTGS2RAPGEF4 | |
| SCHEMBL13597784 | 0.72 | TRPA1 (0.41) | AHR | |
| SCHEMBL18144113 | 0.72 | AHR (0.77) | AHRPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | AHR 1551/4885PTGS1 785/4885PTGS2 1501/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | AHR 1551/4885PTGS1 785/4885PTGS2 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.